113 related articles for article (PubMed ID: 16997177)
1. BL22 and lymphoid malignancies.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2006; 19(4):685-99. PubMed ID: 16997177
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
Kreitman RJ; Squires DR; Stetler-Stevenson M; Noel P; FitzGerald DJ; Wilson WH; Pastan I
J Clin Oncol; 2005 Sep; 23(27):6719-29. PubMed ID: 16061911
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
Kreitman RJ; Stetler-Stevenson M; Margulies I; Noel P; Fitzgerald DJ; Wilson WH; Pastan I
J Clin Oncol; 2009 Jun; 27(18):2983-90. PubMed ID: 19414673
[TBL] [Abstract][Full Text] [Related]
4. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
Kreitman RJ; Wilson WH; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald DJ; Pastan I
N Engl J Med; 2001 Jul; 345(4):241-7. PubMed ID: 11474661
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: BL22, NCI.
Barth S
Curr Opin Mol Ther; 2002 Feb; 4(1):72-5. PubMed ID: 11883697
[TBL] [Abstract][Full Text] [Related]
7. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
8. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
10. Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
Arons E; Sorbara L; Raffeld M; Stetler-Stevenson M; Steinberg SM; Liewehr DJ; Pastan I; Kreitman RJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1100-10. PubMed ID: 16311729
[TBL] [Abstract][Full Text] [Related]
11. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.
Bachanova V; Frankel AE; Cao Q; Lewis D; Grzywacz B; Verneris MR; Ustun C; Lazaryan A; McClune B; Warlick ED; Kantarjian H; Weisdorf DJ; Miller JS; Vallera DA
Clin Cancer Res; 2015 Mar; 21(6):1267-72. PubMed ID: 25770294
[TBL] [Abstract][Full Text] [Related]
13. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Kreitman RJ
Curr Pharm Des; 2009; 15(23):2652-64. PubMed ID: 19689336
[TBL] [Abstract][Full Text] [Related]
14. The disease with hope: hairy cell leukemia.
Becker SE
Clin J Oncol Nurs; 2007 Oct; 11(5):731-5. PubMed ID: 17962181
[TBL] [Abstract][Full Text] [Related]
15. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
Decker T; Oelsner M; Kreitman RJ; Salvatore G; Wang QC; Pastan I; Peschel C; Licht T
Blood; 2004 Apr; 103(7):2718-26. PubMed ID: 14525789
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with 2'-deoxycoformycin.
Catovsky D
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S103-7. PubMed ID: 9137963
[TBL] [Abstract][Full Text] [Related]
17. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
[TBL] [Abstract][Full Text] [Related]
19. CD5+ chronic B-cell leukemia with features intermediate to chronic lymphocytic leukemia and hairy cell leukemia.
Aljurf M; Cornbleet PJ; Michel F
Hematol Pathol; 1994; 8(3):99-109. PubMed ID: 7527021
[TBL] [Abstract][Full Text] [Related]
20. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval.
Lin AY; Dinner SN
Blood Adv; 2019 Oct; 3(19):2905-2910. PubMed ID: 31594764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
